Evidence map›Paper›PMID 40454010›Full record

ArticleACS omega2025

Synthesis and Biological Evaluation of 4‑(4-Nitrophenyl)‑1

Filipe Canto Oliveira, Luís Otávio Bunhotto Zamoner, Marcelo Dias Baruffi, Beatriz Silveira Augusto, Miguel de Menezes Vaidergorn, Maria Cristina Nonato, Thainá Silva Bologna, Marcos Vinicius da Silva, Ivone Carvalho

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Filipe Canto OliveiraDepartment of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Café s/n, Ribeirão Preto, SP 14040-903, Brazil.
Luís Otávio Bunhotto ZamonerDepartment of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Café s/n, Ribeirão Preto, SP 14040-903, Brazil.
Marcelo Dias BaruffiDepartment of Clinical, Toxicological and Bromatological Analysis, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Café s/n, Ribeirão Preto, SP 14040-903, Brazil.
Beatriz Silveira AugustoCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.
Miguel de Menezes VaidergornCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.ORCID https://orcid.org/0000-0003-2343-2888
Maria Cristina NonatoCenter for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP 14040-903, Brazil.ORCID https://orcid.org/0000-0002-4916-1505
Thainá Silva BolognaDepartment of Microbiology, Immunology, and Parasitology, Federal University of Triangulo Mineiro, Av. Frei Paulino 30, Uberaba, MG 38025-180, Brazil.
Marcos Vinicius da SilvaDepartment of Microbiology, Immunology, and Parasitology, Federal University of Triangulo Mineiro, Av. Frei Paulino 30, Uberaba, MG 38025-180, Brazil.ORCID https://orcid.org/0000-0002-2966-7621
Ivone CarvalhoDepartment of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Café s/n, Ribeirão Preto, SP 14040-903, Brazil.ORCID https://orcid.org/0000-0002-2028-777X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chagas disease is endemic to 21 countries across the Americas, with an estimated 6-7 million people infected worldwide. Currently, only two drugsbenznidazole (BZN) and nifurtimoxare approved for treatment. While effective during the acute phase and in preventing mother-to-child transmission, these medications exhibit minimal to no efficacy in the chronic phase, require prolonged treatment courses, and are associated with significant side effects. Building on our previous work, we identified hit

Identifiers

PMID40454010
PMCPMC12120661

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.